Keys to accelerating your COVID-19 drug campaign

CRB – As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.

Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved?

Read more at CRB.